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This post-hoc study was aimed at assessing whether disease severity was higher in a
sample of Treatment Resistant Schizophrenia patients (TRS) compared to schizophrenia
patients responsive to antipsychotics (non-TRS). Determinants of disease severity were
also investigated in these groups. Eligible patients were screened by standardized
diagnostic algorithm to categorize them as TRS or non-TRS. All patients underwent
the following assessments: CGI-S; PANSS; DAI; NES; a battery of cognitive tests.
Socio-demographic and clinical variables were also recorded. TRS patients exhibited
significantly higher disease severity and psychotic symptoms, either as PANSS total
score or subscales’ scores. A preliminary correlation analysis ruled out clinical and
cognitive variables not associated with disease severity in the two groups. Hierarchical
linear regression showed that negative symptoms were the clinical variable explaining
the highest part of variation in disease severity in TRS, while in non-TRS patients
PANSS-General Psychopathology was the variable explaining the highest variation.
Mediation analysis showed that negative symptoms mediate the effects of verbal fluency
dysfunctions and high-level neurological soft signs (NSS) on TRS’ disease severity.
These results show that determinants of disease severity sharply differ in TRS and
non-TRS patients, and let hypothesize that TRS may stem from cognitive disfunctions
and putatively neurodevelopmental aberrations.
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INTRODUCTION
Treatment Resistant Schizophrenia (TRS) is a major challenge in clinical management and therapy
of schizophrenia (1), which per se is among the most relevant causes of morbidity worldwide
(2). TRS is defined as the lack of response to a number of antipsychotic agents, which causes the
patients to be actively symptomatic and to not gain symptom remission and functional recovery (3).
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Accordingly, TRS has been associated to more severe social
disability (4), whose determinants appear to strongly diverge
from that in responder schizophrenia patients (i.e., non-TRS)
(5, 6). Also, TRS may represent a categorically distinct subtype
of schizophrenia (7), as also suggested by clinical data showing
higher severity of neurological soft signs (NSS) in these patients
(8), a marker of aberrant brain development (9).
In this study, we evaluated whether disease severity differed
in TRS vs. non-TRS patients. As a subsequent step, we tried to
delineate the clinical factors influencing disease severity in these
two groups.
METHODS
This post-hoc analysis used data from a previous cross-sectional
naturalistic study (6). Patients’ recruitment continued after
the above-mentioned report, and therefore the present study
includes data from an expanded sample compared to that earlier
one.
Patients were referred to our academic Outpatient Unit
on Treatment Resistant Psychosis, University “Federico II” of
Naples, by community psychiatrists for evaluation of putative
TRS, as they suffered from psychotic symptoms apparently non-
responding to antipsychotic agents. All consecutive patients
meeting criteria for eligibility were recruited.
Inclusion criteria were: (i) age within the 18–65-year
range; (ii) diagnosis of schizophrenia; (iii) being treated with
antipsychotics; (iv) stabilized symptoms, including persistent
psychotic symptoms with no evidence of actual or recent (i.e.,
in the last 3 months prior assessments) worsening. Exclusion
criteria were: (i) intellectual disability (according to DSM-
5 diagnostic criteria); (ii) severe medical diseases; (iii) non-
schizophrenia psychotic disorders; (iv) psychotic symptoms due
to another medical condition or to substances/medications.
All patients signed a written informed consent form, approved
by the local Ethical Committee. All procedures carried out herein
complied with the principles laid down by the Declaration of
Helsinki, revised Hong Kong 1989.
A preliminary screening procedure was carried out for
identifying non-schizophrenia psychotic disorders, pseudo-TRS,
non-TRS, and TRS patients. This procedure has been described
elsewhere (6). For all patients, the following set of clinical-
demographic data were recorded: age; gender; education years;
age at disease onset (AaO); duration of illness (DoI); age at
first psychiatric evaluation; history of substance, alcohol, or drug
abuse; everyday living functional milestones (4). The following
rating scales were administered by two experienced raters: the
Clinical Global Impression-Severity (CGI-S); the Positive and
Negative Syndrome Scale (PANSS); the Neurological Evaluation
Scale (NES) (10); the Drug Attitude Inventory (11).
Patients were assessed for the following cognitive domains’
performances: Sustained and Selective Attention by the
Continuous Performance Task (CPT); Verbal Memory by the
List Learning task; Visuospatial Memory (VSM) by the Brief
Visuospatial Memory test-Revisited; Working Memory by the
Digit Sequencing task; Verbal Fluency by the Category Instances
task and the Controlled Oral Word Association test; Problem
Solving by the Tower of London task; Speed of Information
Processing by the Symbol Coding task. Raw data from each task
were adjusted in corrected scores, according to values in the
Italian normative population (12–14). High corrected scores
corresponded to better preservation of cognitive status.
All statistical procedures were carried out by using the SPSS
24.0 R©. Descriptive statistics were used to report clinical and
socio-demographic data. Independent-sample Student’s T-test
was used to compare quantitative data among diagnostic groups.
In all tests, significance was set at p < 0.05 (two-tailed). Analysis
of correlation was performed by Pearons’s or Spearman’s test, for
continuous and categorical variables respectively. Multivariate
linear regression analysis was used to perform both hierarchical
linear regression (HLR) and mediation analyses.
RESULTS
Group Comparison
A total of 73 schizophrenia patients enrolled in the study
were subdivided in TRS (n = 41) and non-TRS (n = 32)
ones. Age [t(1, 71) = 1.66; p > 0.05], gender (χ = 1.64; p
> 0.05), and education age [t(1, 71) = 1.45; p > 0.05] were
not significantly different between groups. Disease severity and
psychotic symptoms were significantly more severe in TRS
patients compared to non-TRS [Student’s t-test; CGI-S: t(1, 71) =
3.48; p = 0.001; PANSS Positive Score: t(1, 71) = 1.92; p = 0.059;
PANSS Negative Score: t(1, 71) = 3.99; p< 0.0005; PANSS General
Psychopathology (GP) Score: t(1, 71) = 3.21; p = 0.002; PANSS
Total Score: t(1, 71) = 3.79; p< 0.0005] (Figure 1).
Correlation Analysis
In TRS patients, Pearson’s test revealed significant positive
correlations between disease severity and psychotic symptoms
(PANSS Positive: r = 0.51, p = 0.001; PANSS Negative: r = 0.59,
p< 0.0005; PANSS-GP: r = 0.58, p< 0.0005) or NSS (NES score:
r = 0.44, p= 0.005), and inverse significant correlations between
disease severity and verbal fluency performances (r =−0.35, p=
0.03) or VSM score (r =−0.33, p= 0.03).
In non-TRS patients, disease severity showed significant
negative correlations with age (r = −0.38, p = 0.03) and
duration of disease (r =−0.36, p= 0.04) and significant positive
correlations with psychopathology (PANSS Positive: r = 0.50, p
= 0.004; PANSS Negative: r = 0.41, p = 0.02; PANSS-GP: r =
0.56, p = 0.001), but not with NSS. Lifetime work occupation (ρ
= −0.37, p = 0.03), residential status (ρ = −0.40; p = 0.02), and
history of drug abuse (ρ = 0.42; p = 0.02) were also significantly
correlated with disease severity at the Spearman’s ρ test in these
patients.
Hierarchical Linear Regression
We used a hierarchical linear regression (HLR) approach to
evaluate which variables explained the most part of variation
in CGI-S score. PANSS Negative score was the variable that
explained the most variance in CGI-S (Model 1: F = 21.22; p <
0.0005; R2 = 0.36; standardized β= 0.599). PANSS Positive score
was the only other variable whose addition in the model led to
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FIGURE 1 | Disease severity and psychotic symptoms. In this picture are reported TRS and non-TRS groups’ mean scores + standard deviations on the (from left to
right): Clinical Global Impression-Severity (CGI-S) scale; Positive and Negative Syndrome Scale (PANSS) Total score; PANSS Positive Symptoms’ Subscale
(PANSS-P); PANSS Negative Symptoms’ Subscale (PANSS-N); PANSS General Psychopathology Subscale (PANSS-GP). Note the different scales on multiple
graphics. *p < 0.05 at the Student’s t-test. #Trend toward significance (p = 0.06).
a statistically significant increase in R2 (Model 2: F = 17.87; p
< 0.0005; R2 = 0.49; standardized β PANSS Negative = 0.492;
standardized β PANSS Positive= 0.380).
In non-TRS patients, the HLR approach showed that inclusion
of PANSS-GP score explained substantial variation in CGI-S
(Model 1: 13.64; p = 0.001; R2 = 0.313; standardized β = 0.559)
and no other variable added significant variation to the equation.
Mediation Analysis
In order to make the relationships among these variables clearer,
we performed a series of mediation analysis based on the Baron
and Kenny four-step model (15). We started from the hypothesis
that the variables responsible for the highest variance inHLRmay
mediate the relations with disease severity of the variables found
associated to CGI-S in the correlation analysis.
According to correlation analysis, all variables included in the
regression analysis were significant predictors of the outcome
variable CGI-S (Step 1).
In TRS patients, the putative mediator variables were PANSS
Negative score or PANSS Positive score. Verbal Fluency, NSS,
and PANSS Positive score were significant predictors of the
outcome variable PANSS Negative score (Step 2), while VSM
score and PANSS-GP were not (Step 2 not met; analysis stopped).
PANSSNegative score was significantly predictive of the outcome
variable CGI-S when controlled for either Verbal Fluency, NSS,
or PANSS Positive (Step 3). Verbal Fluency and NSS were no
more significantly predictive of CGI-S score when controlled for
PANSS Negative (Step 4), indicating that their relations with
CGI-S may be partially mediated by negative symptoms. On
the contrary, PANSS Positive was still significantly predictive
of CGI-S when controlled for PANSS Negative, indicating
that negative symptoms did not mediate the relation between
positive symptoms and disease severity. VSM score, however, was
significantly predictive of the outcome variable PANSS Positive
(Step 2). PANSS Positive was predictive of CGI-S score after
controlling for VSM score (Step 3), while VSM score was no
more significantly predictive of CGI-S score after controlling
for PANSS Positive (Step 4), thereby indicating that the relation
between VSM and CGI-S was partially mediated by positive
symptoms. Alternative models, using different combinations of
causal and moderator variables, were investigated, however none
of these yielded significant results (data not shown). The results
of this analysis are illustrated in Figure 2A.
In non-TRS patients, mediation analysis showed that the most
important mediator variable was PANSS-GP, which agreed with
results of the HLR. Among the variables correlated with CGI-
S, PANSS Positive, PANSS Negative, and age were significantly
predictive of the outcome variable PANSS-GP (Step 2). PANSS
Positive, PANSS Negative, and age were no more significantly
predictive of CGI-S score when controlled for PANSS-GP (Step
3). PANSS-GP was still significantly predictive of CGI-S score
after controlling for PANSS Positive, PANSS Negative, or age
(Step 4). Alternative models were also investigated. The only
other significant mediation model was found for PANSS Positive
as a mediation variable for age and duration of illness effects on
CGI-S. The results of this analysis are illustrated in Figure 2B.
DISCUSSION
The present work was aimed at dissecting some of the distinctive
clinical features that affect disease severity in schizophrenia
patients responsive to antipsychotic medications compared to
TRS ones. We observed directional relationships among the
variables accounted herein and disease severity, that were
sharply divergent for TRS and non-TRS. Indeed, TRS has been
considered a unique neurobiological clinical entity (16–18), with
its proper pathophysiology, clinical presentation, and disease
course (5, 7). The differences in clinical determinants of disease
severity found in the present study comply with this view.
Notably, in TRS patients the most relevant clinical variable
in determining disease severity was found to be the extent
of negative symptoms. The impact of negative symptoms on
disease severity does not appear attributable to their higher
severity in TRS, since global psychotic symptoms as well as
each psychotic symptom domain have been found more severe
in TRS compared to non-TRS patients herein. Indeed, the
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FIGURE 2 | Graphical rendering of mediation analysis. Panel (A) reports outputs of mediation analysis for the TRS group. Causal variable is on the left and outcome
variable on the right. Significantly associated variables are linked by connection lines. Above connection lines are reported standardized beta values from linear
regression analyses, along with p values (*p < 0.05; **p <.005). For PANSS Negative connection with CGI-S, we reported uncontrolled, Verbal Fluency controlled (a),
and NES controlled (b) standardized betas. Verbal Fluency and NES score were significantly predictive of CGI-S (standardized B = −0.34, p = 0.03; standardized B =
0.438, p = 0.005, respectively), but significance was lost after controlling for PANSS Negative (standardized B = −0.06, p > 0.05; standardized B = 0.218, p >
0.05). For PANSS Positive connection with CGI-s, we reported uncontrolled and VSM controlled (c) standardized betas. VSM was significantly predictive of CGI-S
(standardized B = −0.334, p = 0.03), however significance was lost after controlling for PANSS Positive (standardized B = −0.153, p > 0.05). Panel (B) reports
outputs of mediation analysis for the non-TRS group. For PANSS General Psychopathology (GP) connection with CGI-S, we reported uncontrolled, PANSS Positive
controlled (a), PANSS Negative controlled (b), and age controlled (c) standardized betas. PANSS Positive, PANSS Negative, age, and duration of illness were
significantly predictive of CGI-S (standardized B = 0.500, p = 0.004; standardized B = 0.417, p = 0.02; standardized B = −0.382, p = 0.03; standardized B =
−0.362, p = 0.04, respectively), but significance was lost after controlling for PANSS-GP (standardized B = 0.225, p > 0.05; standardized B = 0.258, p > 0.05;
standardized B = −0.198, p > 0.05, respectively) or PANSS Positive in the case of duration of illness (standardized B = −0.196, p > 0.05).
association between negative symptoms and lack of response to
antipsychotics had been classically reported (19, 20). Also, it has
to be noted that, although being less severe than in TRS patients,
the most relevant clinical variable in determining disease severity
in non-TRS patients was PANSS General Psychopathology
subscale score, which in turn accounts for the effects on
disease severity of positive symptoms, negative symptoms,
and duration of the illness. These elements let hypothesize a
tight and putatively neurobiologically-determined connection
between negative symptoms and TRS, affecting disease severity.
Relevance of negative symptoms on disease severity in TRS
patients may lead to two alternative explanations: (i) patients
with a larger extent of negative symptoms are considered
to be TRS since these symptoms may not be impacted by
antipsychotic agents; indeed, a large metanalysis of randomized
placebo-controlled trials failed to find significant clinical effects
of antipsychotics on negative symptoms (21); (ii) patients with a
TRS suffer from a neurobiologically distinct form of the disease,
which express symptomatically with prominent alterations in
cognitive and negative symptoms. Indeed, there is strong
evidence that cognitive dysfunctions are strictly interconnected
with negative symptoms (22, 23).
The cross-sectional nature of this study does not allow to
solve this issue. However, some clarifications may derive from
mediation analysis. In TRS patients, mediation analysis showed
that negative and positive symptoms directly and independently
affected disease severity. Negative symptoms partially mediated
the effects on disease severity of verbal fluency deficits and
high-level neurological soft signs. Positive symptoms partially
mediated the effects of visuospatial memory deficits. These
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data imply a strong distal effect of cognitive dysfunctions and
neurological soft signs on psychopathology and disease severity
in TRS patients. It has been proposed that cognitive deficits in
schizophrenia may underlie proper and distinct neurobiology
(24). Also, cognitive deficits and severe neurological soft signs
may stem from more relevant neurodevelopmental aberrations
in schizophrenia patients. Therefore, it should be hypothesized
that TRS patients are a subset of schizophrenia patients whose
relevant cognitive deficits and high-level neurological soft signs,
of putative neurodevelopmental origin, in turn determine severe
negative and positive symptoms, affecting disease severity. These
theoretical causal inferences need to be demonstrated by means
of ad hoc designed longitudinal designs.
Notably, determinants of disease severity are sharply divergent
and do not involve neurological soft signs or cognitive alterations.
Indeed, in non-TRS patients, general psychopathology partially
mediated the effects of positive and negative symptoms, age, and
duration of illness on disease severity. These results suggest that
other clinical variables, not accounted herein, may have a major
role in determining disease severity in non-TRS patients.
The results of this study should be interpreted in the light
of its limitations: the sample size was relatively small, although
TRS is a subpopulation of the whole schizophrenia patients and a
representative sample is expected to be lower than that needed to
study schizophrenia; rating scale scores may have been partially
biased by antipsychotic treatment; selection of non-TRS patients
was among patients initially suspected to be non-responsive
to antipsychotic regimens and for this reason referred to our
specialist unit, which may cause inclusion of severe, albeit non-
TRS, patients and may mitigate differences with TRS patients.
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